Bain’s Adam Kop­pel com­mits $350M to launch­ing a new biotech that is carv­ing out Pfiz­er’s neu­ro pipeline

Adam Kop­pel and his team at Bain Cap­i­tal are carv­ing out the neu­ro­sciences pipeline that Pfiz­er shut­tered at the be­gin­ning of the year, set­ting aside $350 mil­lion to back a start­up called Cerev­el which will now take con­trol of the work.

All of the mon­ey for this deal — to be an­nounced lat­er Tues­day morn­ing — is com­ing from Bain Cap­i­tal Pri­vate Eq­ui­ty and Kop­pel’s Bain Cap­i­tal Life Sci­ences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER